Pacific released a research report on April 9 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating. The main reasons for the rating include: 1) the Q4 revenue growth rate is relatively fast, and the performance is slightly lower than expected; 2) the main business growth rate is steady and sales expenses are well controlled; 3) sales reform has achieved remarkable results, expanding incremental space for finished drugs; 4) Continued investment in R&D to open a new era of simulation integration. (Mainichi Keizai Shimbun)
太平洋4月9日发布研报称，给予京新药业（002020.SZ）买入评级。评级理由主要包括：1）Q4收入增速较快，业绩略低于预期；2）主营业务增速稳健，销售费用控制良好；3）销售改革成效显著，成品药拓展增量空间；4）持续投入研发，开启仿创结合新时代。（每日经济新闻）
Pacific released a research report on April 9 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating. The main reasons for the rating include: 1) the Q4 revenue growth rate is relatively fast, and the performance is slightly lower than
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.